title: Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients.
abstract: BACKGROUND
  Anti-tumor-necrosis-factor-alpha agents are limited by their side effects. Eczema is one of the most frequent adverse reactions affecting quality of life.
  
  
  OBJECTIVE
  To assess potential predictive risk factors for eczema in patients receiving infliximab.
  
  
  METHODS
  We conducted a prospective cohort study including patients treated with infliximab for a variety of disorders with the exception of cutaneous psoriasis. Clinical features were compared among patients with and without eczema under therapy.
  
  
  RESULTS
  92 consecutive patients were included; 15 developed eczema after the initiation of infliximab. In univariate analyses, a personal history of atopic symptoms was the only predictive factor for the occurrence of eczema (odds ratio = 3.6). Sex, age, principal diagnosis, dose and duration of infliximab and concomitant use of other immunosuppressors had no influence on the occurrence of eczema.
  
  
  CONCLUSIONS
  A personal history of atopic symptoms is predictive of eczema under infliximab. Specific information should be provided to atopic patients starting such a treatment.
authors.affiliation: Department of Dermatology-Allergology, Tenon Hospital, Paris, France.
authors.forename: Abdolrasool
authors.initials: A
authors.lastname: Esmailzadeh
authors.forename: Pedram
authors.initials: P
authors.lastname: Yousefi
authors.forename: David
authors.initials: D
authors.lastname: Farhi
authors.forename: Claude
authors.initials: C
authors.lastname: Bachmeyer
authors.forename: Jacques
authors.initials: J
authors.lastname: Cosnes
authors.forename: Francis
authors.initials: F
authors.lastname: Berenbaum
authors.forename: Paul
authors.initials: P
authors.lastname: Duriez
authors.forename: Selim
authors.initials: S
authors.lastname: Aractingi
authors.forename: Kiarash
authors.initials: K
authors.lastname: Khosrotehrani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001706:Biopsy; D003424:Crohn Disease / Q000188:drug therapy; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000473:pathology*; D004485:Eczema / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011565:Psoriasis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab